{
  "meta": {
    "data_length": 1,
    "message": "Statement id stmt:ema:verzenios:1:6 retrieved successfully",
    "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Averzenios%3A1%3A6",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001954,
    "timestamp_received": "2026-10-16T23:36:01.466559+00:00Z",
    "timestamp_returned": "2026-10-16T23:36:01.468513+00:00Z",
    "trace_id": "eec23b83-9ff8-4986-aab8-3380402b2776"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:ema:verzenios:1:6",
      "type": "Statement",
      "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-10-20:0",
          "type": "Contribution",
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2018-09-26:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2018-09-26",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:verzenios",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Verzenios (abemaciclib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Eli Lilly Nederland B.V.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Verzenios",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "abemaciclib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2018-10-29",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-03-12",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:9",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:ncit:C9245",
          "conceptType": "Disease",
          "name": "Invasive Breast Carcinoma",
          "mappings": [
            {
              "relation": "exactMatch",
              "coding": {
                "id": "coding:oncotree:BRCA",
                "code": "BRCA",
                "name": "Invasive Breast Carcinoma",
                "system": "https://oncotree.mskcc.org",
                "systemVersion": "oncotree_2025_10_03",
                "iris": [
                  "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Invasive+Breast+Carcinoma+%28BRCA%29"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": true,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C9245",
            "code": "C9245",
            "name": "Invasive Breast Carcinoma",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C9245"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "txgrp:3",
          "membershipOperator": "AND",
          "therapies": [
            {
              "id": "tx:ncit:C1379",
              "conceptType": "Therapy",
              "name": "Fulvestrant",
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:rxcui:282357",
                    "code": "282357",
                    "name": "fulvestrant",
                    "system": "RxNorm",
                    "systemVersion": "20250602",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=282357"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:1304044",
                    "code": "1304044",
                    "name": "fulvestrant",
                    "system": "OMOP",
                    "systemVersion": "v20250827",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1304044"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Estrogen receptor inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Hormone therapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ],
              "primaryCoding": {
                "id": "coding:ncit:C1379",
                "code": "C1379",
                "name": "Fulvestrant",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "26.08e",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"
                ]
              }
            },
            {
              "id": "tx:ncit:C97660",
              "conceptType": "Therapy",
              "name": "Abemaciclib",
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:rxcui:1946825",
                    "code": "1946825",
                    "name": "abemaciclib",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1946825"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:792649",
                    "code": "792649",
                    "name": "abemaciclib",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/792649"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "CDK4/6 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Targeted therapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ],
              "primaryCoding": {
                "id": "coding:ncit:C97660",
                "code": "C97660",
                "name": "Abemaciclib",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "26.08e",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"
                ]
              }
            }
          ]
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:1",
                "present": true,
                "subject": {
                  "id": "bmkr:1",
                  "type": "CategoricalVariant",
                  "name": "ER positive",
                  "constraints": [],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Protein expression"
                    },
                    {
                      "name": "marker",
                      "value": "Estrogen receptor (ER)"
                    },
                    {
                      "name": "unit",
                      "value": "status"
                    },
                    {
                      "name": "equality",
                      "value": "="
                    },
                    {
                      "name": "value",
                      "value": "Positive"
                    }
                  ]
                }
              },
              {
                "id": "bmkr.criterion:2",
                "present": true,
                "subject": {
                  "id": "bmkr:2",
                  "type": "CategoricalVariant",
                  "name": "HER2-negative",
                  "constraints": [],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Protein expression"
                    },
                    {
                      "name": "marker",
                      "value": "Human epidermal growth factor receptor 2 (HER2)"
                    },
                    {
                      "name": "unit",
                      "value": "status"
                    },
                    {
                      "name": "equality",
                      "value": "="
                    },
                    {
                      "name": "value",
                      "value": "Negative"
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "26.08e",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:ema:verzenios:1",
            "type": "Indication",
            "description": "Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2024-10-20:0",
                "type": "Contribution",
                "description": "Adding EMA approvals for use to database",
                "date": "2024-10-20",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:ema:2018-09-26:0",
                "type": "Contribution",
                "description": "Indication received approval from the European Commission.",
                "date": "2018-09-26",
                "contributor": {
                  "id": "agent:org:ema",
                  "type": "Agent",
                  "agentType": "organization",
                  "name": "European Medicines Agency",
                  "description": "Regulatory agency that approves medicines for use in the European Union."
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:ema:verzenios",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Verzenios (abemaciclib) [product information]. EMA.",
                "title": null,
                "aliases": [],
                "description": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.",
                "urls": [
                  "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf",
                  "https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:ema",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "European Medicines Agency",
                      "description": "Regulatory agency that approves medicines for use in the European Union."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "Eli Lilly Nederland B.V.",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": "Verzenios",
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": "abemaciclib",
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": "2018-10-29",
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": null,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2024-03-12",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Active",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Approved",
                "description": "Current approval status."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}